41.50
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Teva Pharmaceutical Industries Ltd Adr Borsa (TEVA) Ultime notizie
Global Brain Health Supplements Market Size, Share, Trends and Forecast, 2026-2035 | Market to Reach USD 35.41 Billion as Natural Products and E-commerce Drive 11% CAGR - GlobeNewswire Inc.
Corcept Looks To End Teva's Mifepristone Antitrust Case - Law360
Small Molecule Active Pharmaceutical Ingredient Market Insights: Demand Trends, Competitive Landscape & Industry Outlook - EIN News
J&J Q3 Earnings Beat Estimates, Sales Miss, View Raised, Stock Down - Zacks Investment Research
ETFs Investing in Teva Pharmaceutical Industries Limited Stocks - TradingView
Teva Pharmaceutical Industries Ltd. to Host R&D Day on November 11, 2026 - Quiver Quantitative
Teva to Host R&D Day on Wednesday, November 11 in New York City - GlobeNewswire Inc.
Teva to Host R&D Day on Wednesday, November 11 in New York City - GlobeNewswire
Teva Pharmaceutical Industries (NYSE:TEVA) Stock Price Target Raised at JPMorgan Chase & Co. - MarketBeat
TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia - Zacks Investment Research
Teva Wins FDA Approval For Schizophrenia Innovation - Healthcare Digital
Teva Pharmaceutical Industries (TEVA): Transitioning from Generics to High-Margin Branded Drugs - Yahoo Finance
ETFs Investing in Teva Pharmaceutical Industries Limited Stocks - TradingView
Pretax income of Teva Pharmaceutical Industries Limited – BMV:TEVA1/N - TradingView
Teva Pharmaceutical Industries (TEVA) Stock Forecasts - Yahoo Finance
Teva Pharmaceutical Industries Ltd (HAM:TEVA) Stock Earnings Transcripts - GuruFocus
Teva Pharmaceutical Industries Ltd (HAM:TEVA) Stock Price, Trades & News - GuruFocus
Teva Pharmaceutical Industries Ltd. Advanced Charts | TEVA - Barron's
Teva Pharmaceutical Industries Ltd. Financials | TEVA - Barron's
Israeli Pharma Giant Teva Wins FDA Approval for Monthly Schizophrenia Injection Weltruza - Haaretz
Teva Pharmaceutical Industries (TEVA) Stock Forecasts - Yahoo! Finance Canada
Teva Pharmaceutical Industries Limited (TEVA) Discusses FDA Approval of Weltruza and Strategic Growth InitiativesSlideshow (NYSE:TEVA) 2026-10-09 - Seeking Alpha
Teva wins FDA approval for monthly schizophrenia injection Weltruza - Reuters
Oppenheimer Adjusts Teva Pharmaceutical Industries PT to $52 From $50, Maintains Outperform Rating - Yahoo Finance
Teva debuts Weltruza in schizophrenia as much-hyped FDA nod for long-acting olanzapine arrives - Fierce Pharma
J&J Stock Ahead of Q3 Earnings: Should You Buy, Sell or Hold? - Zacks Investment Research
Teva Pharmaceutical Industries Ltd. Research & Ratings | TEVA1N - Barron's
Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia - Teva Pharmaceuticals
Teva Pharmaceutical Industries Ltd. Company & People | TEVA - Barron's
Teva Pharmaceutical Industries (NYSE:TEVA) Stock Price - Simply Wall Street
Teva Pharmaceutical Industries (NYSE:TEVA) Stock Forecast & Analyst Predictions - Simply Wall Street
Here's Why You Should Add URGN Stock to Your Portfolio Now - Zacks Investment Research
Teva Pharmaceutical: 3 Numbers That Explain This Generic-Drug Turnaround - The Motley Fool
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Short Interest Update - MarketBeat
Is Teva Pharmaceutical Industries (TEVA) Undervalued Following New Phase 3 Schizophrenia Data? - simplywall.st
Teva, Wyeth Show How Claimed Advances Shape Enablement - Law360
Teva Pharmaceutical Industries Ltd. to Report Third Quarter 2026 Financial Results on November 3, 2026 - quiverquant.com
Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET - GlobeNewswire
Teva Releases Q3 2026 Aide Memoire - GlobeNewswire
Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET - GlobeNewswire Inc.
Teva Releases Q3 2026 Aide Memoire - GlobeNewswire Inc.
Viatris, Teva initiated at Outperform at Oppenheimer - Seeking Alpha
Teva Pharmaceutical Industries(TEVA.US) Director Sells US$14.36 Million in Common Stock - Moomoo
Teva Pharmaceutical Industries (TEVA) Stock Forecasts - finance.yahoo.com
Oppenheimer Initiates Coverage on Teva Pharmaceutical Industries (NYSE:TEVA) - MarketBeat
Teva Eyes New Growth Phase After Securing Investment-Grade Ratings - MarketBeat
Teva Eyes New Growth Phase After Securing Investment-Grade Ratings - Yahoo Finance
TEVA: Investment grade status enables accelerated innovation, robust launches, and renewed generics growth - TradingView
TEVA: Focus shifts to innovation, high-margin launches, and renewed growth in generics and biosimilars - TradingView
Brian Savage Sells 7,342 Shares of Teva Pharmaceutical Industries (NYSE:TEVA) Stock - MarketBeat
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):